Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: An in vivo study using 11C-flumazenil and PET

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1974-1983

  Syvänen, Stina ^a   Labots, Maaike ^a   Tagawa, Yoshihiko ^b   Eriksson, Jonas ^c   Windhorst, Albert D ^c   Lammertsma, Adriaan A ^c   De Lange, Elizabeth C ^a   Voskuyl, Rob A ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Epilepsy; GABAA receptors; P glycoprotein; Pharmacokinetics; Positron emission tomography

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; FLUMAZENIL C 11; KAINIC ACID; MULTIDRUG RESISTANCE PROTEIN; TARIQUIDAR; TRACER; CARBON; DIAGNOSTIC AGENT; FLUMAZENIL; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DISSOCIATION CONSTANT; DRUG BINDING; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; HIPPOCAMPUS; MALE; NONHUMAN; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; TEMPORAL LOBE EPILEPSY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; EPILEPSY; METABOLISM; SCINTISCANNING; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; EPILEPSY; FLUMAZENIL; KAINIC ACID; MALE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 84870308822     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104588     Document Type: Article

References (42)

1. Jefferys JG. Basic mechanisms of focal epilepsies. Exp Physiol. 1990;75:127-162.
2. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol. 2001;63:815-846. (Pubitemid 32304338)
3. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553-564. (Pubitemid 38868551)
4. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4:18-61. (Pubitemid 46107329)
5. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006;129:18-35. (Pubitemid 43063756)
6. Schmidt D, Loscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009;9:47-52.
7. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48:81-87. (Pubitemid 47555379)
8. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76:22-76. (Pubitemid 41033402)
9. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002;125:22-31. (Pubitemid 34084034)
10. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE. Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res. 1998;31:73-84. (Pubitemid 28305406)
11. Racine R, Okujava V, Chipashvili S. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol. 1972;32:295-299.
12. 11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot. 1984;35:973-976.
13. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52:1505-1526. (Pubitemid 46646401)
14. van Velden FH, Kloet RW, van Berckel BN, et al. Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies. Phys Med Biol. 2008;53:99-118.
15. van Velden FH, Kloet RW, van Berckel BN, et al. HRRT versus HR+ human brain PET studies: an interscanner test-retest study. J Nucl Med. 2009;50:693-702.
16. Kuntner C, Bankstahl JP, Bankstahl M, et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging. 2010;37:942-953.
17. 11C]flumazenil and positron emission tomography. Epilepsia. 2009;50:88-98.
18. 11C]flumazenil and positron emission tomography: comparison of full saturation and steady state methods. Neuroimage. 2011;57:928-937.
19. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
20. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152-165.
21. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64. (Pubitemid 29049052)
22. Lamusuo S, Pitkanen A, Jutila L, et al. [11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. Neurology. 2000;54:2252-2260. (Pubitemid 30416275)
23. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol. 2004;73:1-60. (Pubitemid 38749090)
24. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs: a comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002;50:105-123. (Pubitemid 34876591)
25. Liefaard LC, Ploeger BA, Molthoff CF, et al. Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. Mol Imaging Biol. 2005;7:411-421. (Pubitemid 44193406)
26. 11C]Ro15-1788. Neurosci Res. 1996;25:145-154.
27. Visser SA, Wolters FL, Gubbens-Stibbe JM, et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther. 2003;304:88-101. (Pubitemid 36008916)
28. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines: correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther. 1991;257:472-478.
29. 11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. BMC Med Imaging. 2011;11:1-16.
30. Clinckers R, Smolders I, Michotte Y, et al. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. Br J Pharmacol. 2008;155:1127-1138.
31. Syvänen S, Schenke M, van den Berg DJ, Voskuyl RA, de Lange EC. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. AAPS J. 2012;14:87-96.
32. Hammarlund-Udenaes M, Friden M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737-1750.
33. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res. 2006;23:705-717.
34. Bankstahl JP, Bankstahl M, Kuntner C, et al. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci. 2011;31:8803-8811.
35. Bauer M, Karch R, Neumann F, et al. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab. 2010;30:510-515.
36. 11C-verapamil and PET. J Nucl Med. 2008;49:1328-1335.
37. Seegers U, Potschka H, Loscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res. 2002;51:257-268. (Pubitemid 35232571)
38. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res. 1999;126:509-516. (Pubitemid 29281454)
39. Albertson TE, Walby WF, Joy RM. Modification of GABA-mediated inhibition by various injectable anesthetics. Anesthesiology. 1992;77:488-499.
40. Buggy DJ, Nicol B, Rowbotham DJ, Lambert DG. Effects of intravenous anesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition. Anesthesiology. 2000;92:1067-1073. (Pubitemid 30180984)
41. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36:1-6.
42. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42:1501-1506. (Pubitemid 34020086)